Shots:
- The NMPA has approved Exdensur as an add-on therapy for adults with CRSwNP for whom therapy with systemic corticosteroids & /or surgery do not provide adequate disease control, based on P-III (ANCHOR 1 & 2) trials
- The ANCHOR-1 & ANCHOR-2 trial assessed Exdensur(Q6M)+ intranasal corticosteroids (SoC) vs PBO + SoC in 271 & 257 pts, respectively, with inadequately controlled CRSwNP
- ANCHOR-1 (n=271) & ANCHOR-2 (n=257) trials assessed Exdensur vs PBO in CRSwNP pts on intranasal corticosteroids, which showed reduced nasal polyp size at 52wks. & improved nasal obstruction verbal response over Wks. 49-52; data were published in The Lancet
Ref: GSK | Image: GSK | Press Release
Related News: GSK Reports the NMPA Approval of Exdensur (Depemokimab) for Severe Asthma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
